Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Charles Ryan, MD

    TitleAssociate Professor of Clinical
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero St.,MZ Bldg A
    San Francisco CA 94143
    Phone415-353-9279
    Emailryanc@medicine.ucsf.edu

       Overview 
       Overview
      Charles J. Ryan, MD is an Associate Professor of Medicine and Urology at the UCSF Helen Diller Family Comprehensive Cancer Center. where he the Clinical Program Leader for Genitourinary Medical Oncology. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.

      His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.

      His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, insulin growth factor inhibitors, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials Dr Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.

      Dr Ryan is a member of several honor societies and is the recipient of a Leadership and Service Award and the John Kimberly Curtis Award from the University of Wisconsin Medical School. He received the American College of Physicians/ American Society of Internal Medicine Evergreen Award in 2000 and the American Society of Clinical Oncology Merit Award and Cancer And Leukemia Group B: Young Investigator Award, both in 2003. He was awarded the Donald Coffey Career Development Award from the Prostate Cancer Foundation in 2006, a California Coalition to Cure Prostate Cancer Award in 2007 and received the Mentor Award from the Division of Hematology/Oncology in 2011.


       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013 Apr 11; 368(15):1458-9.
        View in: PubMed
      2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
        View in: PubMed
      3. Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Jan; 14(1):91-6.
        View in: PubMed
      4. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1; 19(1):215-24.
        View in: PubMed
      5. Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012 Nov; 39(4):453-64.
        View in: PubMed
      6. Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012 Jun; 13(2):189-200.
        View in: PubMed
      7. Ryan CJ. Abiraterone: current and future use in prostate cancer. Clin Adv Hematol Oncol. 2012 Mar; 10(3):180-1.
        View in: PubMed
      8. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012; 12:78.
        View in: PubMed
      9. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 1; 72(3):616-25.
        View in: PubMed
      10. Bryce A, Ryan CJ. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther. 2012 Jan; 91(1):101-8.
        View in: PubMed
      11. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 1; 9(9):960-77.
        View in: PubMed
      12. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011 Sep 20; 29(27):3651-8.
        View in: PubMed
      13. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
        View in: PubMed
      14. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005.
        View in: PubMed
      15. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
        View in: PubMed
      16. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011; 16(3):264-75.
        View in: PubMed
      17. Ryan C. Abiraterone in prostate cancer. Clin Adv Hematol Oncol. 2010 Nov; 8(11):761-2.
        View in: PubMed
      18. Friedlander TW, Ryan CJ. Editorial comment. J Urol. 2010 Nov; 184(5):1976.
        View in: PubMed
      19. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
        View in: PubMed
      20. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010 Apr; 21(4):433-8.
        View in: PubMed
      21. Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs. 2010 Apr; 19(4):563-70.
        View in: PubMed
      22. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40.
        View in: PubMed
      23. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010 Mar 20; 28(9):1489-95.
        View in: PubMed
      24. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501.
        View in: PubMed
      25. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8.
        View in: PubMed
      26. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer. 2009 Oct 1; 115(19):4470-6.
        View in: PubMed
      27. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6.
        View in: PubMed
      28. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
        View in: PubMed
      29. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol. 2009 May; 19(3):315-21.
        View in: PubMed
      30. Friedlander TW, Ryan CJ. Novel hormonal approaches in prostate cancer. Curr Oncol Rep. 2009 May; 11(3):227-34.
        View in: PubMed
      31. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8.
        View in: PubMed
      32. Need EF, Scher HI, Peters AA, Moore NL, Cheong A, Ryan CJ, Wittert GA, Marshall VR, Tilley WD, Buchanan G. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology. 2009 Jun; 150(6):2674-82.
        View in: PubMed
      33. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
        View in: PubMed
      34. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7.
        View in: PubMed
      35. Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate. 2008 Aug 1; 68(11):1232-40.
        View in: PubMed
      36. Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant prostate cancer. Expert Rev Anticancer Ther. 2008 Feb; 8(2):259-68.
        View in: PubMed
      37. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008 Feb; 101(4):436-9.
        View in: PubMed
      38. Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J. 2008 Jan-Feb; 14(1):11-4.
        View in: PubMed
      39. Harzstark AL, Ryan CJ. Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs. 2008 Jan; 17(1):13-22.
        View in: PubMed
      40. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377.
        View in: PubMed
      41. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol. 2007 Dec; 178(6):2378-83; discussion 2383-4.
        View in: PubMed
      42. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007 Oct; 8(10):933-9.
        View in: PubMed
      43. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4.
        View in: PubMed
      44. Ryan CJ, Beer TM. Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design. J Urol. 2007 Sep; 178(3 Pt 2):S25-9.
        View in: PubMed
      45. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007 Jul 1; 110(1):81-6.
        View in: PubMed
      46. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8.
        View in: PubMed
      47. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
        View in: PubMed
      48. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007 Apr 1; 13(7):2030-7.
        View in: PubMed
      49. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol. 2007 Mar-Apr; 25(2):134-40.
        View in: PubMed
      50. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54.
        View in: PubMed
      51. Ryan CJ, Small EJ. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol. 2006 Dec; 176(6 Pt 2):S61-5.
        View in: PubMed
      52. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006 Dec; 176(6 Pt 2):S66-71.
        View in: PubMed
      53. Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W, Scher HI. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology. 2006 Oct; 68(4):834-9.
        View in: PubMed
      54. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9.
        View in: PubMed
      55. Ryan CJ, Small EJ. Androgen deprivation therapy in locally advanced and metastatic prostate cancer. Minerva Urol Nefrol. 2006 Sep; 58(3):119-26.
        View in: PubMed
      56. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402.
        View in: PubMed
      57. Ryan CJ. Secondary hormonal manipulations in prostate cancer. Hematol Oncol Clin North Am. 2006 Aug; 20(4):925-34.
        View in: PubMed
      58. Ryan CJ, Small EJ. Prostate cancer update: 2005. Curr Opin Oncol. 2006 May; 18(3):284-8.
        View in: PubMed
      59. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3.
        View in: PubMed
      60. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer. 2006 Mar; 4(4):299-302.
        View in: PubMed
      61. Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". J Clin Oncol. 2005 Nov 10; 23(32):8242-6.
        View in: PubMed
      62. Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005 Nov 10; 23(32):8225-31.
        View in: PubMed
      63. Ryan CJ, Small EJ. Progress in detection and treatment of prostate cancer. Curr Opin Oncol. 2005 May; 17(3):257-60.
        View in: PubMed
      64. Ryan CJ, Small EJ. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep. 2005 May; 7(3):228-33.
        View in: PubMed
      65. Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology. 2004 Jul; 64(1):90-4.
        View in: PubMed
      66. Ryan CJ, Small EJ. Advances in prostate cancer. Curr Opin Oncol. 2004 May; 16(3):242-6.
        View in: PubMed
      67. Ryan CJ, Small EJ. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw. 2004 May; 2(3):261-8.
        View in: PubMed
      68. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004 Jan; 164(1):217-27.
        View in: PubMed
      69. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:87-94.
        View in: PubMed
      70. Ryan CJ, Bajorin DF. Chemotherapy for good-risk germ-cell tumors. Semin Urol Oncol. 2002 Nov; 20(4):244-50.
        View in: PubMed
      71. Ryan CJ, Wilding G. Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging. 2000 Oct; 17(4):249-55.
        View in: PubMed
      Charles's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      See all (235) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (24) people
      _
      Related Authors
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Back to TOP